Consistently, the results uncovered that increased sirt3 and IDO1 expression and enhanced sirt3 acetylation levels in the endothelial cells treated with IDO1-overexpression ovarian cancer cell-derived EVs compared with treated with IDO1-knockdown or -control ovarian cancer cell-derived EVs (Fig. 8f). Here, IDO1 is linked to ovarian cancer.